These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23536827)

  • 21. Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany.
    Prestel J; Volkers P; Mentzer D; Lehmann HC; Hartung HP; Keller-Stanislawski B;
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1192-204. PubMed ID: 24817531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.
    Bardage C; Persson I; Ortqvist A; Bergman U; Ludvigsson JF; Granath F
    BMJ; 2011 Oct; 343():d5956. PubMed ID: 21994316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.
    Ghaderi S; Gunnes N; Bakken IJ; Magnus P; Trogstad L; Håberg SE
    Eur J Epidemiol; 2016 Jan; 31(1):67-72. PubMed ID: 26008750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe.
    Dieleman J; Romio S; Johansen K; Weibel D; Bonhoeffer J; Sturkenboom M;
    BMJ; 2011 Jul; 343():d3908. PubMed ID: 21750072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea.
    Kim C; Rhie S; Suh M; Kang DR; Choi YJ; Bae GR; Choi YC; Jun BY; Lee JS
    Vaccine; 2015 Apr; 33(15):1815-23. PubMed ID: 25728315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
    Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
    Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Guillain-Barré Syndrome Among Older Adults Receiving Influenza Vaccine in Taiwan.
    Yen CC; Wei KC; Wang WH; Huang YT; Chang YC
    JAMA Netw Open; 2022 Sep; 5(9):e2232571. PubMed ID: 36129709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing.
    Wu J; Xu F; Lu L; Lu M; Miao L; Gao T; Ji W; Suo L; Liu D; Ma R; Yu R; Zhangzhu J; Liu W; Zeng Y; Li X; Zhang X; Pang X; Deng Y
    N Engl J Med; 2010 Dec; 363(25):2416-23. PubMed ID: 21158658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.
    Verity C; Stellitano L; Winstone AM; Stowe J; Andrews N; Miller E
    Arch Dis Child; 2014 Jun; 99(6):532-8. PubMed ID: 24585755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guillain-Barré syndrome and H1N1 influenza vaccine in UK children.
    Verity C; Stellitano L; Winstone AM; Andrews N; Stowe J; Miller E
    Lancet; 2011 Oct; 378(9802):1545-6. PubMed ID: 22035553
    [No Abstract]   [Full Text] [Related]  

  • 34. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
    Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
    N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guillain-Barré syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009).
    Souayah N; Yacoub HA; Khan HM; Michas-Martin PA; Menkes DL; Maybodi L; Qureshi AI
    Neuroepidemiology; 2012; 38(4):227-32. PubMed ID: 22555646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination.
    Galeotti F; Massari M; D'Alessandro R; Beghi E; Chiò A; Logroscino G; Filippini G; Benedetti MD; Pugliatti M; Santuccio C; Raschetti R;
    Eur J Epidemiol; 2013 May; 28(5):433-44. PubMed ID: 23543123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews.
    Juvet LK; Robertson AH; Laake I; Mjaaland S; Trogstad L
    Front Immunol; 2021; 12():740048. PubMed ID: 34777351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses.
    Grimaldi-Bensouda L; Alpérovitch A; Besson G; Vial C; Cuisset JM; Papeix C; Lyon-Caen O; Benichou J; Rossignol M;
    Am J Epidemiol; 2011 Aug; 174(3):326-35. PubMed ID: 21652600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
    Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.